SHANGHAI, CHINA, October 10, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (hereafter abbreviated as relma-cel, trade name: Carteyva®) for the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL). This is the second approved indication for relma-cel following its initial approval and launch in September last year, and it makes it the first cell immunotherapy product approved in China for the treatment of r/r FL patients.
Siz o'qishni xohlashingiz mumkin: CAR T Xitoyda hujayra terapiyasi
This approval is based on the 6-month clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva® in adult patients with relapsed or refractory B cell non-Hodgkin lymphoma in China. The 3-month data were presented at the 63rd Amerika Gematologiya Jamiyatining (ASH) 2021 yil dekabr oyida yillik yig'ilishi. B kohorti natijalari shuni ko'rsatdiki, Carteyva® kasallikka chidamli javobning juda yuqori sur'atlarini ko'rsatdi (umumiy javob darajasi (ORR) = 100%, 85.19 oyda to'liq javob darajasi (CRR) = 3%; ORR = 92.58%, CRR = 77.78% 6 oy) va nazorat qilinadigan CAR-T r/r FL bo'lgan bemorlarda bog'liq toksiklik. Xitoyda hozirda mavjud davolash usullarini hisobga olgan holda, Carteyva® r/r FL bilan og'rigan bemorlar uchun foyda-xavf nisbati yuqori bo'lgan davolash variantiga aylanishi mumkin va CAR-T sinfidagi eng yaxshi mahsulotga aylanish potentsialiga ega.
Professor Yuqin Song, the principal investigator of RELIANCE study, Deputy Director of the Lymphoma Department, and Vice President of Pekin universiteti saraton kasalxonasi, commented, “The overall response rate (ORR) of the efficacy endpoint was over 90%, and the overall safety profile was manageable. Remal-cel has become the first CAR-T hujayra immunoterapiyasi product for the treatment of the r/r FL in China.”
Siz o'qishni xohlashingiz mumkin: CAR T Xitoyda ko'p miyelom uchun hujayra terapiyasi
James Li, co-founder, chairman, and CEO of JW Therapeutics, said, “Thanks to the patients and investigators who contributed to the clinical studies of Carteyva®, va Karteyvani tan olgani uchun regulyatorlarga rahmat®. We are pleased with the second approved indication, which provides a new and breakthrough treatment option for r/r FL patients. JW Therapeutics is committed to maximizing the value of Carteyva®, continuously advancing technology innovation and pipeline development, and improving the accessibility of cell immunoterapiya mahsulotlar. ”
As the first product of JW Therapeutics and the first CAR-T product approved as a Category 1 biologics product in China, relma-cel has been approved for two indications in China, including the treatment of adult patients with relapsed or refractory large B-cell limfoma (r/r LBCL) after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL). JW Therapeutics is currently doing or plans to do more clinical studies on hematologic malignancies and autoimmune diseases to fully explore the clinical potential of Carteyva®. These include third-line mantiya hujayrali limfoma (MCL), third-line acute lymphoblastic leukemia (ALL), frontline and second-line large B-cell lymphoma (LBCL), and systemic lupus erythematosus (SLE).
Relmacabtagene Autoleucel Injection haqida (savdo nomi: Carteyva®)
Relmacabtagene autoleucel injection, which is also sold under the brand name Carteyva®. It is an autologous anti-CD19 CAR-T hujayrali immunoterapiya product that was built on a CAR-T cell process platform from Juno Therapeutics, a Bristol Myers Squibb company. Being the first product of JW Therapeutics, relma-cel has been approved by the China National Medical Products Administration (NMPA) for two indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only Xitoyda CAR-T mahsuloti u bir vaqtning o'zida muhim yangi dori vositalarini ishlab chiqish milliy dasturiga, ustuvorliklarni ko'rib chiqishga va ilg'or terapiya belgilariga kiritilgan.
Siz o'qishni xohlashingiz mumkin: Xitoyda CAR T Cell terapiyasi narxi
JW Therapeutics haqida
JW Therapeutics (HKEX: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, and is committed to becoming an innovation leader in cell immunotherapy. Founded in 2016, JW Therapeutics has built a world-class platform for product development in cell immunotherapy, as well as a product pipeline covering both hematologic malignancies and solid tumors. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and worldwide, and leading the healthy and standardized development of China’s cell immunotherapy industry.
